Nurix Therapeutics Inc (NRIX)
Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition
📈 **POSITIVE** • High confidence analysis (81%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (94%) **Content type:** Clinical